Menu

SPL-006: An Open-label Phase 1 Trial of the Safety and Efficacy of Daily Subcutaneous SPL-108 Injections When Used in Combination with Paclitaxel in Patients with Platinum-resistant, CD44+, Advanced Ovarian Epithelial Cancer.

Print this page

SPL-006: An Open-label Phase 1 Trial of the Safety and Efficacy of Daily Subcutaneous SPL-108 Injections When Used in Combination with Paclitaxel in Patients with Platinum-resistant, CD44+, Advanced Ovarian Epithelial Cancer.

The objectives of this trial are to:
Primary Objective
h Determine the safety of SPL-108 in combination with paclitaxel
(PTX) under the conditions of the trial.
Secondary Objective
h Document any observed efficacy of daily subcutaneous (SC)
injections of SPL-108 when administered in combination with
PTX in women with CD44+ ovarian cancer whose disease has
progressed or recurred after platinum-based chemotherapy.

Protocol Number: 051607
Phase: Phase I
Applicable Disease Sites: Ovary
Drugs Involved: SPL-108
PACLITAXEL
Principal Investigator: Lorna Rodriguez
Research Nurse: Melissa Frankel
For additional information about this trial, contact the Research Nurse listed above
Scope: Local
Therapies Involved: Chemotherapy multiple agents systemic
Participating Institutions: Rutgers Cancer Institute of New Jersey
Inclusion & Exclusion Criteria

Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site www.clinicaltrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria. For additional information on this trial or other available clinical trials please contact the research nurse.

For further information about clinical trials, please contact us at 732-235-8675.

 

precision medicine at Rutgers Cancer Institute

 

 

 

ScreenNJ

 

 

Donate Now

 

 

 


 

 

 

 

Proud member of
Big Ten Cancer Research Consortium

 

 

Rutgers Health